“…In the first year of Comirnaty® rollout, it is estimated that the vaccine contributed to averting almost 9 million symptomatic cases, 700,000 hospitalizations, and over 110,000 deaths. 33 This was made possible by progressing our vaccine development program swiftly, going from the first 10 mL IVT reaction run to the first drug product lot with an EUA in 3 months (Figure 5). Our team and collaborators did this while successfully ensuring the highest compliance and quality standards according to the normal vaccine development principles: 19 1.…”